A Multinational Observational Registry Collecting Data on safety and efficacy profile of Patients with Chronic Hepatitis D Virus Infection Receiving Treatment with Bulevirtide - MYR-Reg-02

MYR GmbH0 个研究点目标入组 45 人开始时间: 2021年2月4日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. HBsAg-positive, adult (=18 years) patients who have been diagnosed with chronic HDV infection according to current EASL/ AASLD treatment guidelines, confirmed by respective documentation in the patients’ medical records.
•2. Patients currently receiving treatment with bulevirtide (trade name: Hepcludex®) according to the current version of the SmPC; or for whom the decision to start treatment with BLV according to the current version of the SmPC has been taken and treatment initiation is planned; or patients who previously received treatment with BLV according to the previously valid version of the SmPC (not in the framework of a clinical trial).
•3. Patients who have provided written informed consent or non-opposition according to local requirements.

•Patients cannot be enrolled into the study if they are currently participating in a clinical trial with experimental treatment.

发起方